Who Does Mounjaro Not Work For — and When Might It Be the Wrong Choice?

Medical reasons a prescriber may rule Mounjaro out completely

Some conditions make tirzepatide unsuitable regardless of how much someone wants to try it. A personal or family history of medullary thyroid carcinoma or MEN2 is a clear contraindication in the prescribing guidance; animal studies raised a thyroid-tumour signal and caution is applied across this patient group. A history of severe pancreatitis also warrants careful assessment, in January 2026 the MHRA issued a Drug Safety Update confirming acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines, and prescribers factor this in from the outset.

Certain serious gastrointestinal conditions (gastroparesis, inflammatory bowel disease in an active flare) may also make Mounjaro inappropriate, because slowing gastric emptying further could worsen the underlying problem. Severe kidney or liver disease requires individual prescriber judgement. Under-18s are not a licensed population. Pregnancy, breastfeeding, and actively trying to conceive all sit firmly outside the recommended use; the MHRA advises contraception throughout treatment and for a defined wash-out period afterwards. For women taking oral contraceptives, UK guidance notes that for the first four weeks of Mounjaro and for four weeks after each dose increase, a non-oral method should be added, absorption of the pill can be reduced. You can read more about the full mechanism and pharmacology, including how Mounjaro works for weight loss, on our page explaining how Mounjaro works.

None of this is exhaustive. A GPhC-registered prescriber reviews the complete medical picture; the list above covers the patterns that most commonly result in Mounjaro being declined.

When Mounjaro is technically suitable but the response is limited

Being eligible on paper and seeing a strong response in practice are two different things. Several factors reduce how much weight someone loses, without making the medicine unsafe or wrong for them in an absolute sense.

Dose matters considerably. Tirzepatide's licensed schedule starts at 2.5 mg, a dose whose primary job is helping the body adjust, not producing significant weight loss. The weight-loss effect builds as the dose increases, and the SURMOUNT-1 trial results (published in the New England Journal of Medicine) showed the largest average reductions at 15 mg. Someone who cannot tolerate escalation beyond 5 mg will generally see a more modest outcome than the headline figures suggest.

Lifestyle context plays a real role too. Mounjaro reduces appetite and slows gastric emptying, but it works alongside a reduced-calorie diet and increased physical activity, that combination is part of its licensed indication, not an optional extra. People who find those changes hardest to sustain consistently tend to see smaller losses. Certain medicines (steroids, some antipsychotics, specific diabetes treatments) can counteract the weight-related effects and need a prescriber's eye.

Underlying conditions such as hypothyroidism that is not yet well-controlled, or insulin resistance that hasn't been addressed, can limit the response. These are reasons to have a thorough clinical conversation, not reasons to assume the medicine has failed. Our overview of whether Mounjaro works for some people and not others goes into this variation in more detail.

The 5% threshold, and what happens when it isn't met

NICE's appraisal of tirzepatide (TA1026) includes a built-in review point: if someone has not lost at least 5% of their starting body weight after six months on the highest dose they can tolerate, continuing the treatment should be clinically reassessed. This isn't a punishment, it is a recognition that treatment works substantially better for some people than others, and that carrying on when there is minimal response exposes someone to side effects and cost without proportionate benefit.

In private practice a prescriber applies the same logic. If your weight loss has stalled completely, the sensible next step is a conversation about why, not simply continuing at the same dose indefinitely. Sometimes the explanation is practical: inconsistent injection timing, storage issues, a period of high stress or medication change. Sometimes the dose genuinely needs revisiting. And sometimes a different approach altogether is the better answer.

If you are already on treatment and wondering why progress has slowed, this page on personal non-response to Mounjaro works through those reasons specifically. For a broader sense of what the evidence says about when and why the medicine falls short, our page on whether Mounjaro can simply not work covers the clinical picture plainly.

How to decide whether Mounjaro is right for your situation

This decision sits with a prescriber, not with a checklist. The questions worth arriving with are: Do I have any of the contraindicated conditions? Am I taking medicines that might reduce the effect? Are there lifestyle or health factors that are not yet optimised? What are my expectations, and are they grounded in the trial evidence?

The trial data (involving thousands of adults across the SURMOUNT programme) showed average body-weight reductions of around 20–21% at the highest dose over 72 weeks. That average conceals real variation: some participants lost substantially more, some substantially less. Understanding that range before you start makes it easier to read your own progress honestly rather than comparing yourself to a headline figure.

Cost is also part of the picture, though it is rarely the most important part. The Mounjaro price page sets out what private treatment typically involves in the UK. It's worth reading before you commit, as UK list prices shifted significantly in 2025.

Our prescribers review every consultation personally, your answers land with a clinician, not a screening algorithm. If you want to talk through whether tirzepatide makes sense given your medical history, start a free consultation and a prescriber will work through it with you. There's no obligation, and most people find it a relief just to have a clear answer either way.